Patents by Inventor Pablo Umaña

Pablo Umaña has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMMON LIGHT CHAINS AND METHODS OF USE
    Publication number: 20170253670
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 7, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Ekkehard Moessner, Ralf Hosse, Peter Bruenker, Pablo Umana, Christiane Neumann
  • BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
    Publication number: 20170247467
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) four moieties capable of specific binding to a costimulatory TNF receptor family member, (b) at least one moiety capable of specific binding to a target cell antigen, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 29, 2016
    Publication date: August 31, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: MARIA AMANN, PETER BRUENKER, CHRISTINA CLAUS, CLAUDIA FERRARA KOLLER, SANDRA GRAU-RICHARDS, RALF HOSSE, CHRISTIAN KLEIN, VIKTOR LEVITSKI, SAMUEL MOSER, PABLO UMANA
  • Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
    Patent number: 9718885
    Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: August 1, 2017
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, James E. Bailey
  • TREATMENT METHOD
    Publication number: 20170209573
    Abstract: The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.
    Type: Application
    Filed: December 7, 2016
    Publication date: July 27, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Stefan Evers, Christian Klein, Pavel Pisa, Eva Rossmann, Jose Saro, Pablo Umana
  • BISPECIFIC ANTIGEN BINDING MOLECULES
    Publication number: 20170198043
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: October 20, 2016
    Publication date: July 13, 2017
    Applicant: Roche Glycart AG
    Inventors: Johannes Auer, Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Wolfgang Schaefer, Claudio Sustmann, Pablo Umana
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170190783
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: July 6, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christianne Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170174786
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: June 22, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Christian Klein, Wolfgang Schaefer, Stefan Klostermann, Sabine Imhof-Jung, Michael Molhoj, Joerg Thomas Regula, Pablo Umana, Sylvia Herter, Christiane Neumann
  • METHOD AND CONSTRUCTS FOR THE pH DEPENDENT PASSAGE OF THE BLOOD-BRAIN-BARRIER
    Publication number: 20170174776
    Abstract: Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.
    Type: Application
    Filed: December 1, 2015
    Publication date: June 22, 2017
    Applicant: Roche Glycart AG
    Inventors: Bernd Bohrmann, Per-Ola Freskgard, Adrian Hugenmatter, Erhard Kopetzki, Ekkehard Moessner, Jens Niewoehner, Hadassah Sumum Sade, Pablo Umaña
  • Bispecific anti-EGFR/anti IGF-1R antibodies
    Patent number: 9650442
    Abstract: The present invention relates to bispecific anti-EGFR/anti IGF-1R antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: May 16, 2017
    Assignee: Roche Glycart AG
    Inventors: Ralf Hosse, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Cuiying Shao, Lei Shi, Pablo Umana, Peng Wang, Katharina Wartha
  • BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3
    Publication number: 20170114135
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 29, 2016
    Publication date: April 27, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Bispecific T cell activating antigen binding molecules
    Publication number: 20170114146
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 27, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Wolfgang Schaefer, Stefan Klostermann, Sabine Imhof-Jung, Michael Molhoj, Joerg Thomas Regula, Tanja Fauti, Charles Dumontet, Pablo Umana, Marina Bacac, Anne Freimoser-Grundschober
  • BISPECIFIC ANTIBODIES SPECIFIC FOR A COSTIMULATORY TNF RECEPTOR
    Publication number: 20170114141
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 29, 2016
    Publication date: April 27, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: MARIA AMANN, PETER BRUENKER, CHRISTINA CLAUS, CLAUDIA FERRARA KOLLER, SANDRA GRAU-RICHARDS, RALF HOSSE, CHRISTIAN KLEIN, VIKTOR LEVITSKI, PABLO UMANA
  • Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
    Patent number: 9631023
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: April 25, 2017
    Assignee: ROCHE GLYCART AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, James E. Bailey
  • A-FUCOSYLATION DETECTION IN ANTIBODIES
    Publication number: 20170108510
    Abstract: This invention describes a new analytical method to determine the quantity and distribution of fucose per Fc within an antibody preparation.
    Type: Application
    Filed: June 10, 2016
    Publication date: April 20, 2017
    Applicant: Roche Glycart AG
    Inventors: Christiane Jaeger, Hans Koll, Peter Sondermann, Pablo Umana
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170096495
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 29, 2016
    Publication date: April 6, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Thomas HOFER, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Tapan NAYAK, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMAÑA, Tina WEINZIERL
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170096485
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 29, 2016
    Publication date: April 6, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Gerhard NIEDERFELLNER, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMAÑA
  • NOVEL IMMUNOCONJUGATES
    Publication number: 20170088631
    Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Application
    Filed: July 1, 2016
    Publication date: March 30, 2017
    Applicant: Roche Glycart AG
    Inventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
  • COMBINATION IL-2 IMMUNOCONJUGATE THERAPY
    Publication number: 20170056522
    Abstract: The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.
    Type: Application
    Filed: November 16, 2016
    Publication date: March 2, 2017
    Applicant: Roche Glycart AG
    Inventors: Christian Gerdes, Christian Klein, Valeria G. Nicolini, Pablo Umana
  • BISPECIFIC HER2 ANTIBODIES AND METHODS OF USE
    Publication number: 20170029529
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: June 17, 2016
    Publication date: February 2, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale, Lydia Jasmin Duerner, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • Combination IL-2 immunoconjugate therapy
    Patent number: 9526797
    Abstract: The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: December 27, 2016
    Assignee: Roche Glycart AG
    Inventors: Christian Gerdes, Christian Klein, Valeria G. Nicolini, Pablo Umana